What Evidence Can and Cannot Show About Reglan and Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Exposure Concerns

If you or a loved one has taken Reglan and noticed uncontrollable facial or limb movements, you may be worried about tardive dyskinesia. Decades of pharmacovigilance have established that long-term use of metoclopramide can cause this potentially irreversible movement disorder. This page reviews what the medical evidence can and cannot prove about causation, and outlines current monitoring recommendations for New Jersey patients.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with documented gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, total treatment duration should also be avoided beyond 12 weeks; if longer use is unavoidable, routine monitoring for signs of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Clinical Presentation and Mechanism of Tardive Dyskinesia

The clinical presentation of TD includes involuntary movements such as grimacing, sticking out the tongue, lip smacking, puckering, or rapid eye blinking. These movements can also involve the trunk and extremities. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide. The condition may be irreversible even after discontinuation of the drug. Metoclopramide can also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway involves chronic blockade of dopamine D2 receptors in the basal ganglia, leading to upregulation of receptors and subsequent hypersensitivity, which manifests as involuntary movements.

Risk Context and Adequacy of Warnings

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning explicitly states the risk, the importance of shortest duration of treatment, and the need to discontinue immediately if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring or warning. The label also notes that Reglan has not been shown to be safe and effective for gastroesophageal reflux beyond 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For pediatric patients, the drug is not recommended due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Tardive Dyskinesia Claims in New Jersey

Settlement-related considerations for affected patients in New Jersey involve the statute of limitations, which is the time limit within which a lawsuit must be filed. In New Jersey, the statute of limitations for personal injury claims, including those related to drug-induced TD, is generally two years from the date the injury was discovered or should have been discovered. This means that patients who developed TD after taking Reglan must file a claim within two years of recognizing the link between their symptoms and the medication. The timeline between exposure and documented harm is critical: TD often develops after months or years of use, and symptoms may appear after discontinuation. The boxed warning emphasizes that risk increases with duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who took Reglan for longer than 12 weeks, especially those with diabetic gastroparesis, are at higher risk. The label advises that if longer-term use is unavoidable, routine monitoring for TD is necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For settlement purposes, evidence of inadequate warnings or failure to monitor may strengthen claims. The FDA label includes explicit warnings, but if a physician prescribed Reglan for extended periods without informing the patient of TD risk, or if the manufacturer failed to update warnings adequately, liability may be pursued. Patients should document the duration of Reglan use, the onset of TD symptoms, and any medical records showing lack of monitoring. The statute of limitations in New Jersey requires prompt action once the injury is discovered. Given the potentially irreversible nature of TD, early legal consultation is advisable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those related to drug-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered. This means patients must file a claim within two years of recognizing the link between their symptoms and Reglan use.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through chronic blockade of dopamine D2 receptors in the basal ganglia, leading to receptor upregulation and hypersensitivity. This results in involuntary, repetitive movements. The risk increases with duration of treatment and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.